Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized, Blinded, Positive-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and Above

Authors not listed

Guangzhou Patronus Biotech Co., Ltd. · 2022

Abstract

This is a randomized, blinded, positive-controlled study to evaluate the safety and immnunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, in population aged 18 years old and above. 100 subjects will be recruited in this study, including 50 aged 18-59 years old and 50 aged 60 years old and above.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-07 MST

Cite this

APA
Anonymous. (2022). A Randomized, Blinded, Positive-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and Above. <em>Guangzhou Patronus Biotech Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT05552573
Vancouver
Anonymous. A Randomized, Blinded, Positive-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and Above. Guangzhou Patronus Biotech Co., Ltd.. 2022.
BibTeX
@misc{anon2022ARando, title = {A Randomized, Blinded, Positive-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and Above}, author = {Anonymous}, journal = {Guangzhou Patronus Biotech Co., Ltd.}, year = {2022}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings